Current Treatment Options in Gastroenterology

, Volume 16, Issue 4, pp 541–547 | Cite as

The Role of Botox in Colorectal Disorders

  • Dan Carter
  • Ram DickmanEmail author
Motility (H Parkman and R Schey, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Motility


Purpose of review

To overview the current medical literature on the efficacy of botulism toxin treatment (BTX-A) for lower gastrointestinal disorders (GIT).

Recent findings

BTX-A was found to have a short-term efficacy for the treatment of dyssynergic defecation. Surgical treatment was found to be more effective than BTX-A for the healing of chronic anal fissures, and BTX-A can be considered when surgery is undesirable. Data regarding the effects of BTX-A injection for the treatment of chronic anal pain is limited. Beneficial effects were observed only in a minority of patients. BTX-A treatment was found to be effective for the treatment of obstructive symptoms after surgery for Hirsprung’s disease as well as for the treatment of internal anal sphincter achalasia.


BTX-A treatment has a short-term efficacy and is safe. Further research is still needed in order to establish the exact place of BTX-A treatment of lower GIT disorders.


Botox Dyssynergic defecation Chronic anal pain Anal fissure Hirsprung’s disease Internal anal sphincter achalasia 


Compliance with Ethical Standards

Conflict of Interest

Dan Carter reports personal fees from Takeda, Abbvie, and Janssen, outside the submitted work. Ram Dickman declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Albanese A, Brisinda G, Mathias CJ. The autonomic nervous system and gastrointestinal disorders. In: Appenzeller O, Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology, vol. 75. Amsterdam: Amsterdam North-Holland Pub. Co; 2000. p. 613–63.Google Scholar
  2. 2.
    •• Emile SH, Elfeki HA, Elbanna HG, et al. Efficacy and safety of botulinum toxin in treatment of anismus: a systematic review. World J Gastrointest Pharmacol Ther. 2016;7:453–62 This review provides a thorough evaluation of BTX-A in pelvic dyssynergia.CrossRefGoogle Scholar
  3. 3.
    Brisinda G, Sivestrini N, Bianco G, Maria G. Treatment of gastrointestinal sphincters spasms with botulinum toxin A. Toxins. 2015;7:1882–916.CrossRefGoogle Scholar
  4. 4.
    Bharucha AE. Pelvic floor: anatomy and function. Neurogastroenterol Motil. 2006;18:507–19.CrossRefGoogle Scholar
  5. 5.
    Rao SS, Tuteja AK, Vellema T, et al. Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol. 2004;38:680–5.CrossRefGoogle Scholar
  6. 6.
    Kuijpers HC, Bleijenberg G. The spastic pelvic floor syndrome. A cause of constipation. Dis Colon Rectum. 1985;28:669–72.CrossRefGoogle Scholar
  7. 7.
    Andromanakos N, Skandalakis P, Troupis T, Filippou D. Constipation of anorectal outlet obstruction: pathophysiology, evaluation and management. J Gastroenterol Hepatol. 2006;21:638–46.CrossRefGoogle Scholar
  8. 8.
    Patcharatrakul T, Rao SSC. Update on the pathophysiology and management of anorectal disorders. Gut Liver. 2018;12:375–84.CrossRefGoogle Scholar
  9. 9.
    Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186–94.CrossRefGoogle Scholar
  10. 10.
    Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF. Treatment of anismus in intractable constipation with botulinum a toxin. Lancet. 1988;2:714–7.CrossRefGoogle Scholar
  11. 11.
    Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD. Initial north American experience with botulinum toxin type a for treatment of anismus. Dis Colon Rectum. 1996;39:1107–11.CrossRefGoogle Scholar
  12. 12.
    Shafik A, El-Sibai O. Botulin toxin in the treatment of nonrelaxing puborectalis syndrome. Dig Surg. 1998;15:347–51.CrossRefGoogle Scholar
  13. 13.
    Ron Y, Avni Y, Lukovetski A, Wardi J, Geva D, Birkenfeld S, et al. Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum. 2001;44:1821–6.CrossRefGoogle Scholar
  14. 14.
    Farid M, El Monem HA, Omar W, et al. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Color Dis. 2009;24:115–20.CrossRefGoogle Scholar
  15. 15.
    Maria G, Cadeddu F, Brandara F, Marniga G, Brisinda G. Experience with type a botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol. 2006;101:2570–5.CrossRefGoogle Scholar
  16. 16.
    Zhang Y, Wang ZN, He L, Gao G, Zhai Q, Yin ZT, et al. Botulinum toxin type-a injection to treat patients with intractable anismus unresponsive to simple biofeedback training. World J Gastroenterol. 2014;20:12602–7.CrossRefGoogle Scholar
  17. 17.
    Farid M, Youssef T, Mahdy T, Omar W, Moneim HA, El_Nakeeb A, et al. Comparative study between botulinum toxin injection and partial division of puborectalis for treating anismus. Int J Color Dis. 2009;24:327–34.CrossRefGoogle Scholar
  18. 18.
    Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22:997–1003.CrossRefGoogle Scholar
  19. 19.
    Hompes R, Harmston C, Wijffels N, Jones OM, Cunningham C, Lindsey I. Excellent response rate of anismus to botulinum toxin if rectal prolapse misdiagnosed as anismus (‘pseudoanismus’) is excluded. Color Dis. 2012;14:224–30.CrossRefGoogle Scholar
  20. 20.
    Whitehead WE, Wald A, Diamant NE, et al. Functional disorders of the anus and rectum. Gut. 1999;45:1155–9.Google Scholar
  21. 21.
    Grimaud JC, Bouvier M, Naudy B, Guien C, Salducci J. Manometric and radiologic investigations and biofeedback treatment of chronic idiopathic anal pain. Dis Colon Rectum. 1991;34:690–5.CrossRefGoogle Scholar
  22. 22.
    Jeyarajah S, Chow A, Ziprin P, et al. Proctalgia fugax, an evidence-based management pathway. Int J Color Dis. 2010;9:1037–46.CrossRefGoogle Scholar
  23. 23.
    Atkin GK, Suliman A, Vaizey CJ. Patient characteristics and treatment outcome in functional anorectal pain. Dis Colon Rectum. 2011;54:870–5.CrossRefGoogle Scholar
  24. 24.
    Christiansen J, Bruun E, Skjoldbye B, Hagen K. Chronic idiopathic anal pain: analysis of ultrasonography, pathology, and treatment. Dis Colon Rectum. 2001;44:661–5.CrossRefGoogle Scholar
  25. 25.
    Hollingshead JR, Maeda Y, Brown TJ, et al. Long-term outcome of the use of botulinum toxin injection for functional anal pain. Color Dis. 2011;13:293–6.CrossRefGoogle Scholar
  26. 26.
    •• Mapel DW, Schum M, Von Worley A. The epidemiology and treatment of anal fissures in a population-based cohort. BMC Gastroenterol. 2014;14:129 This review provides a thorough evaluation of different treatments for anal fissures and the role of BTX-A.CrossRefGoogle Scholar
  27. 27.
    Lindsey I, Jones OM, Cunningham C, Mortensen NJMC. Chronic anal fissure. Br J Surg. 2004;91:270–9.CrossRefGoogle Scholar
  28. 28.
    Herzig DO, Lu KC. Anal fissure. Surg Clin North Am. 2010;90:33–44.CrossRefGoogle Scholar
  29. 29.
    Griffin N, Acheson AG, Tung P, Sheard C, Glazebrook C, Scholefield JH. Quality of life in patients with chronic anal fissure. Color Dis. 2004;6:39–44.CrossRefGoogle Scholar
  30. 30.
    Liratzopoulos N, Efremidou EI, Papageorgiou MS, Kouklakis G, Moschos J, Manolas KJ, et al. Lateral subcutaneous internal sphincterotomy in the treatment of chronic anal fissure: our experience. J Gastrointestin Liver Dis. 2006;15(2):143–7.PubMedGoogle Scholar
  31. 31.
    Garg P, Garg M, Menon GR. Long-term continence disturbance after lateral internal sphincterotomy for chronic anal fissure: a systematic review and meta-analysis. Color Dis. 2013;15:104–17.CrossRefGoogle Scholar
  32. 32.
    Chen HL, Woo XB, Wang HS, Lin YJ, Luo HX, Chen YH, et al. Botulinum toxin injection versus lateral internal sphincterotomy for chronic anal fissure: a meta-analysis of randomized control trials. Tech Coloproctol. 2014;18:693–8.CrossRefGoogle Scholar
  33. 33.
    Altomare DF, Rinaldi M, Milito G, Arcana F, et al. Glyceryl trinitrate for chronic anal fissure—healing or headache? Results of a multicenter, randomized, placebo-controlled double blind trial. Dis Colon Rectum. 2000;43:174–9.CrossRefGoogle Scholar
  34. 34.
    Antripoli C, Perrotti P, Rubino M, Martino A, et al. Nifedipine for local use in conservative treatment of anal fissures: preliminary results of a multicenter study. Dis Colon Rectum. 1999;42:1011–5.CrossRefGoogle Scholar
  35. 35.
    Bielecki K, Kolodziejczak M. A prospective randomized trial of diltiazem and glyceryltrinitrate ointment in the treatment of chronic anal fissure. Color Dis. 2003;5:256–7.CrossRefGoogle Scholar
  36. 36.
    Jensen SL. Treatment of first episodes of acute anal fissure: a prospective randomised study of lignocaine ointment versus hydrocortisone ointment or warm sitz baths plus bran. Br Med J. 1986;292:1167–70.CrossRefGoogle Scholar
  37. 37.
    Eshghi F. The efficacy of L-arginine gel for treatment of chronic anal fissure compared to surgical sphincterotomy. J Med Sci. 2007;7:481–4.CrossRefGoogle Scholar
  38. 38.
    Gaj F, Trecca A, Crispino P. Efficacy of anal dilators in the treatment of acute anal fissure. A controlled clinical trial. Chir Ital. 2006;58:761–5.PubMedGoogle Scholar
  39. 39.
    Gupta P. Randomized, controlled study comparing sitzbath and no-sitz-bath treatments in patients with acute anal fissures. ANZ J Surg. 2006;76:718–21.CrossRefGoogle Scholar
  40. 40.
    Jensen SL. Maintenance therapy with unprocessed bran in the prevention of acute anal fissure recurrence. J R Soc Med. 1987;80:296–8.CrossRefGoogle Scholar
  41. 41.
    Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. Am J Surg. 2000;179:46–50.CrossRefGoogle Scholar
  42. 42.
    Brisinda G, Maria G, Sganga G, Bentivoglio AR, Albanese A, Castagneto M. Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery. 2002;131:179–84.CrossRefGoogle Scholar
  43. 43.
    Nelson RL, Thomas K, Morgan J, et al. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2012;15(2):CD00343.Google Scholar
  44. 44.
    Sahebally SM, Meshkat B, Walsh SR, Beddy D. Botulinum toxin injection vs topical nitrates for chronic anal fissure: an updated systematic review and meta-analysis of randomized controlled trials. Color Dis. 2018;20:6–15.CrossRefGoogle Scholar
  45. 45.
    Arroyo A, Perez F, Serrano P, et al. Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure: long-term results of a prospective randomized clinical and manometric study. Am J Surg. 2005;189:429–34.CrossRefGoogle Scholar
  46. 46.
    Minguez M, Herreros B, Espi A, et al. Long-term follow-up (42 months) of chronic anal fissure after healing with botulinum toxin. Gastroenterology. 2002;123:112–7.CrossRefGoogle Scholar
  47. 47.
    Mentes BB, Irkorucu O, Akin, et al. Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum. 2003;46:232–7.CrossRefGoogle Scholar
  48. 48.
    Davies J, Duffy D, Boyt N, Aghahoseini A, Alexander D, Leveson S. Botulinum toxin (botox) reduces pain after hemorrhoidectomy: results of a double-blind, randomized study. Dis Colon Rectum. 2003;46:1097–102.CrossRefGoogle Scholar
  49. 49.
    Chumpitazi BP, Nurko S. Defecation disorders in children after surgery for Hirschsprung disease. J Pediatr Gastroenterol Nutr. 2011;53:75–9.CrossRefGoogle Scholar
  50. 50.
    Langer JC. Persistent obstructive symptoms after surgery for Hirschsprung’s disease: development of a diagnostic and therapeutic algorithm. J Pediatr Surg. 2004;39:1458–62.CrossRefGoogle Scholar
  51. 51.
    Neilson IR, Yazbeck S. Ultrashort Hirschsprung’s disease: myth or reality. J Pediatr Surg. 1990;25:1135–8.CrossRefGoogle Scholar
  52. 52.
    Minkes RK, Langer JC. A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung’s disease. J Pediatr Surg. 2000;35:1733–6.CrossRefGoogle Scholar
  53. 53.
    Han-Geurts IJ, Hendrix VC, de Blaauw I, et al. Outcome after anal intrasphincteric botox injection in children with surgically treated Hirschsprung disease. J Pediatr Gastroenterol Nutr. 2014;59:604–7.CrossRefGoogle Scholar
  54. 54.
    Friedmacher F, Puri P. Comparison of posterior internal anal sphincter myectomy and intrasphincteric botulinum toxin injection for treatment of internal anal sphincter achalasia: a meta-analysis. Pediatr Surg Int. 2012;28:765–71.CrossRefGoogle Scholar
  55. 55.
    •• Church JT, Gadepalli SK, Talishinsky T, et al. Ultrasound-guided intrasphincteric botulinum toxin injection relieves obstructive defecation due to Hirschsprung’s disease and internal anal sphincter achalasia. J Pediatr Surg. 2017;52:74–8 This study examines the efficacy of a targeted BTX-A treatment in Hirschsprung’s disease and internal anal sphincter achalasia.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of GastroenterologyChaim Sheba Medical CenterRamat GanIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityRamat AvivIsrael
  3. 3.Division of GastroenterologyRabin Medical CenterPetah TikvaIsrael

Personalised recommendations